| AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Co.'s sufentanil sublingual products and product candidates include DSUVIA®, which is indicated for use in adults in supervised healthcare settings; Zalviso®, which is intended for the management of moderate-to-severe acute pain in hospitalized adult patients; and ARX-02, which is for cancer breakthrough pain in opioid-tolerant patients. We show 47 historical shares outstanding datapoints in our ACRX shares outstanding history coverage, used to compute ACRX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACRX market cap history over the course of time is important for investors
interested in comparing ACRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACRX versus a peer is one thing; comparing
ACRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACRX can fluctuate over the course of history.
With this page we aim to empower investors researching ACRX by allowing them to research the ACRX market cap history.